$MGNX

MacroGenics reported $288M in cash as of September 30, 2026, and a runway through 2028. Clinical updates include MGC026's 27.3% response rate in SCCHN, lorigerlimab's 25% response in clear cell gynecologic cancer, and MGC028's Phase 1 completion. The company expects further updates in mid-2027 and the first half of 2027, respectively. MacroGenics also noted $359M in non-dilutive capital generated in 2025-2026.

MacroGenics reported Q3 GAAP EPS of -$0.32, missing estimates by $0.28. Revenue was $18.67M, down 64.8% year-over-year and missing expectations by $20.51M. The company's performance fell short of analysts' projections.

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress • Completed MGC028 Phase 1 dose escalation; selected lead indication for dose optimization across two dose levels • Reported interim results at ESMO in both Phase 1 stud

MacroGenics Inc (MGNX) reported Q3 EPS of -$0.29, matching estimates, but revenue of $36.6M missed the $40.6M consensus. The stock is down 42.82% over 3 months but up 69.85% year-over-year. InvestingPro rates its financial health as 'fair performance'.

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors ROCKVILLE, MD, November 3, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing in

MacroGenics (MGNX) reported positive interim Phase 2 data for lorigerlimab in clear cell gynecologic cancer (CCGC), showing a 25% ORR and 44% DCR. The safety profile was manageable. The company is enrolling more patients and expects updated results in 2027.

MacroGenics (MGNX) filed an 8-K with the SEC on October 23, 2026, reporting corporate changes and voting matters. The filing includes exhibits related to the disclosure. Investors should review the details for potential impacts on the company's governance and operations.

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Other Events. MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN • Durable responses observed across multiple tumor types during dose escalation • MGC026 demonstrated 27% best overall response rate (6/22 pati

MacroGenics reported positive Phase 1 results for MGC026, showing a 27% response rate in SCCHN patients. The company plans to start a front-line combination study with pembrolizumab in early 2027. The data suggests potential for earlier-line use, pending further trials.

MacroGenics has dosed the first patient in a Phase I trial for MGC030, an antibody-drug conjugate targeting advanced solid tumors. The trial will assess pharmacokinetics, safety, and antitumour activity. The company expects to enroll up to 54 patients initially, with potential expansion. According to MacroGenics, preclinical data showed encouraging antitumour activity.